Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Neurology

Treating CPA: The Balance of Care

At a Glance

Cerebral proliferative angiopathy is usually managed by protecting healthy brain tissue: active surveillance and symptom treatment are common, while procedures are reserved for a high-risk aneurysm, fistula, or selected patients with severely reduced blood flow.

Treating Cerebral Proliferative Angiopathy (CPA) presents a unique challenge that doctors often call a “treatment paradox.” In many other brain conditions, the goal is to remove or destroy the abnormal tissue. However, in CPA, because healthy, functioning brain tissue is woven into the abnormal vessels, aggressive treatments can often cause more harm than the disease itself [1][2].

Active Surveillance is Often Common

For many patients, a common course of action is active surveillance, sometimes referred to as observation [3]. This means your medical team will monitor you closely with regular imaging (like MRI or MRA) and clinical exams rather than performing surgery or radiation [4][5].

This approach is often preferred because:

  • High Risk of Complications: Research has shown that aggressive interventions like diffuse surgery or major embolization in CPA patients are associated with a high rate of complications, such as strokes or new neurological deficits [6][7].
  • Preserving Function: Since your “healthy” brain lives inside the “sick” vessels, removing the network would mean removing part of your functional brain [8][1].
  • Recurrence: Even if a portion of the network is treated, the “proliferative” nature of the condition suggests a risk that abnormal vessels may recruit or progress over time [9][10].

Managing Symptoms

While the vascular network itself may not be globally treated, the symptoms it causes are very treatable.

  • Seizures: Doctors use standard anti-epileptic medications (seizure meds) to keep the brain’s electrical activity stable [11].
  • Headaches: Chronic headaches are managed with supportive care and specific headache protocols tailored to your needs [12].
  • Low Blood Flow: In some individual cases, medications like cilostazol have been used to try and improve blood flow, though this is not a routine standard treatment and carries bleeding risks; never start or stop it without your specialist’s explicit advice [13].

Targeted Treatment: “The Culprit Lesion”

While doctors generally avoid treating the entire web of vessels, they may step in to treat a specific “culprit lesion” if one is found [14]. Using Digital Subtraction Angiography (DSA), your team looks for high-risk features that are more likely to cause a bleed.

  • Aneurysms: If a small bulge (aneurysm) is found on one of the vessels, doctors may use coil embolization—placing tiny metal coils inside the bulge to block it off—without deliberately targeting the rest of the network [15][4].
  • Fistulas: If there is a specific spot where an artery and vein are connected too directly (a fistula), that single spot might be targeted for treatment [14].

Indirect Revascularization: A Possible Solution?

For some patients, the biggest problem is hypoperfusion (severely low blood flow). In these cases, a surgical technique called indirect revascularization—such as EDAS (Encephaloduroarteriosynangiosis)—may be considered [16][17].

In this procedure, a surgeon takes a healthy blood vessel from your scalp and lays it directly onto the surface of the brain. Over several months, the “hungry” brain may grow new, healthy connections to that vessel to get the oxygen it needs [18][19].

This is not a “cure,” and it is an investigational or selectively used option typically recommended if you have progressive symptoms and objective evidence of impaired reserve [16][17]. The evidence for this treatment in CPA is still growing, and it carries perioperative risks like stroke or bleeding [16][3].

Why Traditional AVM Treatments are Discouraged

If you read about standard Arteriovenous Malformations (AVMs), you will see treatments like surgical resection (cutting it out) or stereotactic radiosurgery (targeted radiation). In CPA, these are generally avoided:

  • Resection: Because the lesion is “diffuse” (spread out) and mixed with brain tissue, complete removal is usually not possible or desirable [1].
  • Radiosurgery: While it can shrink some vessels, it takes years to work, and the radiation risks damaging the healthy brain tissue that is mixed into the diffuse CPA network, making it generally unsuitable for treating the entire lesion [20][21].

Your team’s goal is to find the balance between managing your risks and protecting your quality of life [22][3].

Common questions in this guide

Why is monitoring CPA often safer than treating the entire vascular network?
In CPA, functioning brain tissue is mixed into the abnormal blood-vessel network. Removing or blocking the entire network can cause a stroke or new neurological problems, so doctors often use regular MRI or MRA scans and clinical examinations to monitor it. This approach is called active surveillance.
How are seizures and headaches treated when the CPA network is not removed?
Seizures are treated with standard anti-seizure medicines, while headaches are managed with an individualized headache plan and supportive care. Tell your clinicians about worsening or new symptoms so treatment can be adjusted.
When might a doctor treat one part of a CPA vascular network?
Digital subtraction angiography can help identify a high-risk problem, such as an aneurysm or a direct artery-to-vein connection called a fistula. Doctors may treat that specific area, for example with coil embolization, without deliberately targeting the rest of the network.
Could EDAS help improve low blood flow in cerebral proliferative angiopathy?
Indirect revascularization, such as EDAS, may be considered when CPA causes severely reduced blood flow together with progressive symptoms and objective evidence that the brain’s blood-flow reserve is impaired. It is a selective or investigational option, not a cure, and it carries risks such as stroke or bleeding.
Why are standard AVM surgery and radiosurgery usually avoided in CPA?
CPA is diffuse, meaning its abnormal vessels are spread through functioning brain tissue, so complete surgical removal is usually not possible or desirable. Radiosurgery can take years to work and may damage healthy tissue within the network, making whole-network treatment generally unsuitable.
What should I discuss with my CPA team before choosing observation or a procedure?
Ask how much functioning brain tissue is within the vascular network, whether a proposed procedure targets a specific high-risk lesion, and why observation is or is not appropriate now. You can also ask about the team’s experience with CPA and the plan for seizures, headaches, or worsening neurological symptoms.

Get notified when new evidence is published on Cerebral proliferative angiopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (22)
  1. 1

    Cerebral Proliferative Angiopathy in a Child, Five Years after an Intraventricular Hemorrhage and Negative Catheter Angiography.

    Singfer U, Baert E, Defreyne L

    Journal of the Belgian Society of Radiology 2023; (107(1)):55 doi:10.5334/jbsr.3247.

    PMID: 37546522
  2. 2

    Diffuse Proliferative Cerebral Angiopathy: A case report and review of the literature.

    Rohit , Goh PS

    Journal of radiology case reports 2015; (9(9)):1-10 doi:10.3941/jrcr.v9i9.2402.

    PMID: 26629303
  3. 3

    A Proposed Algorithm for Managing Cerebral Proliferative Angiopathy.

    Chen YN, Lee CW, Xiao F, et al.

    World neurosurgery 2022; (167()):e360-e369 doi:10.1016/j.wneu.2022.08.009.

    PMID: 35961587
  4. 4

    Long-term hemodynamic changes in cerebral proliferative angiopathy presenting with intracranial hemorrhage: illustrative case.

    Saito T, Harada K, Kajihara M, et al.

    Journal of neurosurgery. Case lessons 2023; (5(16)).

    PMID: 37070681
  5. 5

    Cerebral proliferative angiopathy accompanied by cerebral cavernous malformation: A case report.

    Engin EF, Polat B, Ertan Akan G, Akgül E

    Clinical neurology and neurosurgery 2021; (210()):107011 doi:10.1016/j.clineuro.2021.107011.

    PMID: 34741975
  6. 6

    Presentation and management of cerebral proliferative angiopathy: a systematic review and meta-analysis on treatment outcomes.

    Palavani LB, Mitre LP, Almeida MV, et al.

    Neurosurgical review 2024; (47(1)):664 doi:10.1007/s10143-024-02878-z.

    PMID: 39312085
  7. 7

    Embolization of ruptured arteriovenous malformations in the cerebellopontine angle cistern.

    Endo H, Osawa SI, Matsumoto Y, et al.

    Neurosurgical review 2018; (41(1)):173-182 doi:10.1007/s10143-017-0832-1.

    PMID: 28220368
  8. 8

    Cerebral Proliferative Angiopathy: Imaging Spectrum and Diagnostic Insights.

    Rai P, Chan VEY, Lakhani DA, et al.

    AJNR. American journal of neuroradiology 2026; (47(7)):1776-1784 doi:10.3174/ajnr.A9122.

    PMID: 41326231
  9. 9

    Microsurgical resection of previously embolized recurrent cerebellopontine angle AVM.

    Dowlati E, Chesney K, Nayar VV

    Neurosurgical focus: Video 2021; (4(1)):V2 doi:10.3171/2020.10.FOCVID2057.

    PMID: 36284624
  10. 10

    Recurrence of Cerebral Arteriovenous Malformation Following Complete Obliteration Through Endovascular Embolization.

    Hao Q, Zhang H, Han H, et al.

    Translational stroke research 2025; (16(2)):339-349 doi:10.1007/s12975-023-01215-8.

    PMID: 37957446
  11. 11

    The Treatment of Symptomatic Diffuse Proliferative Cerebral Angiopathy With Cilostazol: A Case Report.

    Gautam D, Morrison DE, Bounajem MT, et al.

    Cureus 2024; (16(6)):e63387 doi:10.7759/cureus.63387.

    PMID: 39070371
  12. 12

    Ischemic stroke revealing diffuse cerebral proliferative angiopathy-A case report.

    Mojahid A, Mahi NE, Siouri H, et al.

    Radiology case reports 2025; (20(7)):3621-3624 doi:10.1016/j.radcr.2025.04.012.

    PMID: 40469266
  13. 13

    Cerebral proliferative angiopathy with papilledema.

    Kumar S, Srivastava T, Tejwani S, Khilnani K

    Clinical neurology and neurosurgery 2015; (139()):12-5.

    PMID: 26355910
  14. 14

    Targeted endovascular treatment of haemorrhagic posterior fossa proliferative angiopathy.

    Giragani S, Pavunesan SK, Balasubramaniam A

    Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences 2018; (24(4)):440-443 doi:10.1177/1591019918761640.

    PMID: 29554843
  15. 15

    De novo ruptured intracranial aneurysm associated with cerebral proliferative angiopathy: illustrative case.

    Suetsugu H, Okawa S, Ishibashi T, et al.

    Journal of neurosurgery. Case lessons 2026; (12(7)).

    PMID: 42607334
  16. 16

    Cerebral revascularization in cerebral proliferative angiopathy: a systematic review.

    Somji M, McEachern J, Silvaggio J

    Neurosurgical focus 2019; (46(2)):E11.

    PMID: 30717067
  17. 17

    Progressive Cerebral Ischemia and Intracerebral Hemorrhage after Indirect Revascularization for a Patient with Cerebral Proliferative Angiopathy.

    Kimiwada T, Hayashi T, Takahashi M, et al.

    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2019; (28(4)):853-858 doi:10.1016/j.jstrokecerebrovasdis.2018.11.021.

    PMID: 30737070
  18. 18

    Anesthetic Management for Encephaloduroarteriosynangiosis in Moyamoya Disease: A Hemodynamic and Neuromonitoring-Integrated Framework.

    Chauhan V

    Journal of clinical medicine 2026; (15(13)) doi:10.3390/jcm15134954.

    PMID: 42452416
  19. 19

    Encephaloduroarteriomyosynangiosis with the middle meningeal artery for proliferative cerebral angiopathy treatment: A case report.

    Xochipa-Ruiz KE, Lara-Torres F, Casas-Martínez MR, et al.

    Surgical neurology international 2025; (16()):438 doi:10.25259/SNI_855_2025.

    PMID: 41216168
  20. 20

    Stereotactic radiosurgery for deep intracranial arteriovenous malformations, part 1: Brainstem arteriovenous malformations.

    Cohen-Inbar O, Ding D, Chen CJ, Sheehan JP

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2016; (24()):30-6.

    PMID: 26740034
  21. 21

    Predictors of radiation-induced changes in arteriovenous malformation patients undergoing radiosurgery: Insights from a Malaysian linear accelerator cohort.

    Tan BH, Kandasamy R, Mohamad SA, Thambinayagam HC

    Surgical neurology international 2024; (15()):223 doi:10.25259/SNI_366_2024.

    PMID: 38974554
  22. 22

    Cerebral proliferative angiopathy in pediatric patients: case-based review with an illustrative case.

    Moskalik AD, Mo J, Sawyerr M, et al.

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2026; (42(1)):62 doi:10.1007/s00381-026-07129-8.

    PMID: 41652190

This page is for informational purposes only and does not constitute medical advice. Your neurovascular team can explain which surveillance, symptom treatments, or procedures are appropriate for your CPA.

Guide contents Cerebral proliferative angiopathy
Research & Literature
03 Mapping the Network 05 Building Your Care Team